Literature DB >> 30824585

BRAF Inhibition: Bridge or Boost to T-cell Therapy?

Stephanie L Goff1, Steven A Rosenberg2.   

Abstract

The concept of treatment-refractory disease has evolved as checkpoint modulation has changed the therapeutic landscape for patients with metastatic melanoma. Developing meaningful salvage strategies will involve the exploration of combination therapies and new immunotherapeutics, including adoptive transfer of tumor-infiltrating lymphocytes or other T-cell-based therapy.See related article by Atay et al., p. 2783. ©2019 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30824585      PMCID： PMC6497532          DOI： 10.1158/1078-0432.CCR-19-0286

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  17 in total

1.  Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor.

Authors:  Anna Pasetto; Alena Gros; Paul F Robbins; Drew C Deniger; Todd D Prickett; Rodrigo Matus-Nicodemos; Daniel C Douek; Bryan Howie; Harlan Robins; Maria R Parkhurst; Jared Gartner; Katarzyna Trebska-McGowan; Jessica S Crystal; Steven A Rosenberg
Journal:  Cancer Immunol Res       Date:  2016-06-28       Impact factor: 11.151

Review 2.  'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.

Authors:  Eric Tran; Paul F Robbins; Steven A Rosenberg
Journal:  Nat Immunol       Date:  2017-02-15       Impact factor: 25.606

3.  BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells.

Authors:  Cigdem Atay; Taekyoung Kwak; Sergio Lavilla-Alonso; Laxminarasimha Donthireddy; Allison Richards; Valerie Moberg; Shari Pilon-Thomas; Michael Schell; Jane L Messina; Vito W Rebecca; Min Xiao; Jiufeng Tan; Gao Zhang; Jeffrey S Weber; Meenhard Herlyn; Amod A Sarnaik; Dmitry I Gabrilovich
Journal:  Clin Cancer Res       Date:  2019-02-14       Impact factor: 12.531

4.  Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.

Authors:  Laszlo G Radvanyi; Chantale Bernatchez; Minying Zhang; Patricia S Fox; Priscilla Miller; Jessica Chacon; Richard Wu; Gregory Lizee; Sandy Mahoney; Gladys Alvarado; Michelle Glass; Valen E Johnson; John D McMannis; Elizabeth Shpall; Victor Prieto; Nicholas Papadopoulos; Kevin Kim; Jade Homsi; Agop Bedikian; Wen-Jen Hwu; Sapna Patel; Merrick I Ross; Jeffrey E Lee; Jeffrey E Gershenwald; Anthony Lucci; Richard Royal; Janice N Cormier; Michael A Davies; Rahmatu Mansaray; Orenthial J Fulbright; Christopher Toth; Renjith Ramachandran; Seth Wardell; Audrey Gonzalez; Patrick Hwu
Journal:  Clin Cancer Res       Date:  2012-10-02       Impact factor: 12.531

5.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

6.  A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma.

Authors:  Drew C Deniger; Mei Li M Kwong; Anna Pasetto; Mark E Dudley; John R Wunderlich; Michelle M Langhan; Chyi-Chia Richard Lee; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2016-10-07       Impact factor: 12.531

7.  Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

Authors:  Nadeem Riaz; Jonathan J Havel; Vladimir Makarov; Alexis Desrichard; Walter J Urba; Jennifer S Sims; F Stephen Hodi; Salvador Martín-Algarra; Rajarsi Mandal; William H Sharfman; Shailender Bhatia; Wen-Jen Hwu; Thomas F Gajewski; Craig L Slingluff; Diego Chowell; Sviatoslav M Kendall; Han Chang; Rachna Shah; Fengshen Kuo; Luc G T Morris; John-William Sidhom; Jonathan P Schneck; Christine E Horak; Nils Weinhold; Timothy A Chan
Journal:  Cell       Date:  2017-10-12       Impact factor: 41.582

8.  Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.

Authors:  Shari Pilon-Thomas; Lisa Kuhn; Sabine Ellwanger; William Janssen; Erica Royster; Suroosh Marzban; Ragini Kudchadkar; Jonathan Zager; Geoffrey Gibney; Vernon K Sondak; Jeffrey Weber; James J Mulé; Amod A Sarnaik
Journal:  J Immunother       Date:  2012-10       Impact factor: 4.456

9.  Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

Authors:  Antoni Ribas; Omid Hamid; Adil Daud; F Stephen Hodi; Jedd D Wolchok; Richard Kefford; Anthony M Joshua; Amita Patnaik; Wen-Jen Hwu; Jeffrey S Weber; Tara C Gangadhar; Peter Hersey; Roxana Dronca; Richard W Joseph; Hassane Zarour; Bartosz Chmielowski; Donald P Lawrence; Alain Algazi; Naiyer A Rizvi; Brianna Hoffner; Christine Mateus; Kevin Gergich; Jill A Lindia; Maxine Giannotti; Xiaoyun Nicole Li; Scot Ebbinghaus; S Peter Kang; Caroline Robert
Journal:  JAMA       Date:  2016-04-19       Impact factor: 56.272

10.  Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.

Authors:  Michal J Besser; Ronnie Shapira-Frommer; Orit Itzhaki; Avraham J Treves; Douglas B Zippel; Daphna Levy; Adva Kubi; Noa Shoshani; Dragoslav Zikich; Yaara Ohayon; Daniel Ohayon; Bruria Shalmon; Gal Markel; Ronit Yerushalmi; Sara Apter; Alon Ben-Nun; Eytan Ben-Ami; Avichai Shimoni; Arnon Nagler; Jacob Schachter
Journal:  Clin Cancer Res       Date:  2013-05-20       Impact factor: 12.531
View more
  1 in total

Review 1.  Surgical Considerations and Systemic Therapy of Melanoma.

Authors:  Adriana C Gamboa; Michael Lowe; Melinda L Yushak; Keith A Delman
Journal:  Surg Clin North Am       Date:  2019-11-01       Impact factor: 2.741
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.